Philipp M
Fortschr Med. 1977 Jan 13;95(2):107-10.
The new migraine preparation Migraeflux has been subjected to clinical trial in a double-blind cross-over study in 32 single tests. Compared with other products, the 2-phase-preparation Migraeflux is distinguished--due to its antihistaminic ingredient--by the capacity of preventing in 2/3 of the cases the formation of a migraine attack if applied soon during the prodromal phase. If the attack is not prevented, the intensity of pain is lessened in 70% of the remaining cases and the duration of attack is markedly reduced. The preparation proved to be tolerated very well.
新型偏头痛药物Migraeflux已在一项双盲交叉研究中接受了32次单项测试的临床试验。与其他产品相比，两阶段制剂Migraeflux因其抗组胺成分而与众不同，即在先兆期尽早使用时，它有能力在三分之二的病例中预防偏头痛发作的形成。如果发作未得到预防，在其余70%的病例中疼痛强度会减轻，且发作持续时间会显著缩短。该制剂耐受性良好。
